A systematic review of the effectiveness of adalimumab

More documents

Recommendations

Info

226 Appendix 10 TABLE 164 Variation 18: TNF inhibitors third (late RA values) (100,000 patients) Option Cost (£) QSE QALYs QSE Adal 58,576 109 5.5927 0.0147 Etan 70,549 129 6.3112 0.0156 Adal+MTX 58,583 107 5.8779 0.0147 Etan+MTX 70,423 128 6.2830 0.0157 Infl+MTX 58,374 105 5.6291 0.0148 Base 27,469 43 5.3622 0.0137 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 31,107 103 0.2305 0.0141 Etan – Base 43,080 121 0.9489 0.0151 Ad+M – Base 31,114 102 0.5156 0.0142 Et+M – Base 42,954 121 0.9208 0.0152 In+M – Base 30,906 99 0.2669 0.0142 Ad+M – Adal 7 136 0.2851 0.0144 Etan – Et+M 126 159 0.0281 0.0161 Etan – Adal 11,973 149 0.7184 0.0152 Et+M – Ad+M 11,840 148 0.4052 0.0153 Ad+M – In+M 209 134 0.2488 0.0145 Et+M – In+M 12,048 147 0.6540 0.0153 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 135,000 120,000 to 154,000 Etan – Base 45,400 44,000 to 46,900 Ad+M – Base 60,300 57,200 to 63,900 Et+M – Base 46,600 45,100 to 48,300 In+M – Base 116,000 105,000 to 130,000 Ad+M – Adal Adal+MTX more effective than Adal alone; diff. cost not significant Etan – Et+M Comparison is inconclusive Etan – Adal 16,700 15,900 to 17,500 Et+M – Ad+M 29,200 27,100 to 31,800 Ad+M – In+M Adal+MTX more effective than Infl+MTX; diff. cost not significant Et+M – In+M 18,400 17,500 to 19,500 TABLE 165 Variation 18: TNF inhibitors last (20,000 patients) Option Cost (£) QSE QALYs QSE Adal 50,104 239 1.8630 0.0220 Etan 61,587 282 2.9782 0.0267 Adal+MTX 49,663 234 2.1603 0.0223 Etan+MTX 61,732 283 2.9730 0.0271 Infl+MTX 50,066 231 1.9151 0.0226 Base 18,262 81 1.0336 0.0183 Comparison Diff. cost (£) QSE Diff. QALY QSE Adal – Base 31,842 227 0.8293 0.0160 Etan – Base 43,325 267 1.9446 0.0228 Ad+M – Base 31,401 223 1.1267 0.0171 Et+M – Base 43,470 266 1.9393 0.0233 In+M – Base 31,804 220 0.8815 0.0169 Adal – Ad+M 440 303 –0.2974 0.0204 Et+M – Etan 144 352 –0.0053 0.0298 Etan – Adal 11,484 332 1.1153 0.0253 Et+M – Ad+M 12,068 330 0.8126 0.0264 In+M – Ad+M 402 297 –0.2452 0.0214 Et+M – In+M 11,666 325 1.0578 0.0262 continued
TABLE 165 Variation 18: TNF inhibitors last (20,000 patients) (cont’d) © Queen’s Printer and Controller <strong>of</strong> HMSO 2006. All rights reserved. Health Technology Assessment 2006; Vol. 10: No. 42 Comparison ICER (£ per QALY) Quasi-CI Adal – Base 38,400 36,900 to 40,000 Etan – Base 22,300 21,700 to 22,900 Ad+M – Base 27,900 27,000 to 28,800 Et+M – Base 22,400 21,800 to 23,000 In+M – Base 36,100 34,700 to 37,600 Ad+M – Adal Adal+MTX more effective than Adal alone; diff. cost not significant Et+M – Etan Comparison is inconclusive Etan – Adal 10,300 9,540 to 11,100 Et+M – Ad+M 14,900 13,700 to 16,200 In+M – Ad+M Adal+MTX more effective than Infl+MTX; diff. cost not significant Et+M – In+M 11,000 10,200 to 11,900 227
Page 1 and 2:
A systematic review of the effectiv
Page 3 and 4:
A systematic review of the effectiv
Page 5 and 6:
Objectives: This report reviews the
Page 7:
Glossary and list of abbreviations
Page 10 and 11:
viii Glossary and list of abbreviat
Page 13 and 14:
Background Rheumatoid arthritis (RA
Page 15:
increased risk of serious infection
Page 19 and 20:
Summary RA is a common, chronic, in
Page 21 and 22:
(IL-2) and interleukin-6 (IL-6), pr
Page 23 and 24:
Assessment of response to DMARDs Re
Page 25 and 26:
combination with methotrexate or al
Page 27:
disease between clinic appointments
Page 30 and 31:
14 Effectiveness in juvenile arthri
Page 32 and 33:
16 Effectiveness adalimumab plus me
Page 34 and 35:
18 Effectiveness Monoclonal Antibod
Page 36 and 37:
20 TABLE 1 Description of included
Page 38 and 39:
22 TABLE 2 Quality of included RCTs
Page 40 and 41:
24 Effectiveness change in modified
Page 42 and 43:
26 Effectiveness TABLE 4 Meta-analy
Page 44 and 45:
28 Effectiveness Review: Adalimumab
Page 46 and 47:
30 Effectiveness Review: Adalimumab
Page 48 and 49:
32 TABLE 6 Effectiveness Descriptio
Page 50 and 51:
34 TABLE 6 Effectiveness Descriptio
Page 52 and 53:
36 TABLE 7 Effectiveness Quality of
Page 54 and 55:
38 Effectiveness etanercept trials.
Page 56 and 57:
40 Effectiveness TABLE 9 Summary of
Page 58 and 59:
42 Effectiveness Review: Etanercept
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
54 Effectiveness TABLE 11 Summary o
Page 72 and 73:
56 TABLE 12 Description of included
Page 74 and 75:
58 TABLE 13 Quality of included RCT
Page 76 and 77:
60 Effectiveness per week and escal
Page 78 and 79:
62 Effectiveness significant advant
Page 80 and 81:
64 Effectiveness Review: Infliximab
Page 82 and 83:
66 Effectiveness Review: Infliximab
Page 84 and 85:
68 Effectiveness FIGURE 44 Malignan
Page 86 and 87:
70 TABLE 17 Effectiveness Summary o
Page 89 and 90:
Summary of review of existing econo
Page 91 and 92:
TABLE 20 Summary of published ICERs
Page 93 and 94:
TABLE 21 Published etanercept econo
Page 95 and 96:
TABLE 23 Published economic analyse
Page 97 and 98:
TABLE 25 Treatment sequences: adali
Page 99 and 100:
management of RA, i.e. 1st and 2nd
Page 101 and 102:
To estimate the long-term consequen
Page 103 and 104:
TABLE 32 TNF inhibitors as last act
Page 105 and 106:
TABLE 34 Basic structure of the mod
Page 107 and 108:
een quit on grounds of toxicity, ad
Page 109 and 110:
TABLE 39 Strategy set: adalimumab a
Page 111 and 112:
TABLE 43 Beta distributions for HAQ
Page 113 and 114:
TABLE 44 Early cessation of DMARDs:
Page 115 and 116:
TABLE 46 Unit costs for tests and v
Page 117 and 118:
following properties, according to
Page 119 and 120:
TABLE 52 Base case: TNF inhibitors
Page 121 and 122:
TABLE 54 Base case: TNF inhibitors
Page 123 and 124:
TABLE 59 Third TNF inhibitor follow
Page 125 and 126:
TABLE 65 Sensitivity analyses: TNF
Page 127 and 128:
TABLE 67 Sensitivity analyses: TNF
Page 129:
The substantial economic impact of
Page 133 and 134:
Summary Effectiveness: principal fi
Page 135 and 136:
inhibitors, although the incrementa
Page 137 and 138:
introduce bias which generally exag
Page 139:
Adalimumab, etanercept and inflixim
Page 143 and 144:
1. Jobanputra P, Barton P, Bryan S,
Page 145 and 146:
46. Young A, Dixey J, Cox N, Davies
Page 147 and 148:
tumor necrosis factor therapy in th
Page 149 and 150:
arthritis: a 12-week, double-blind,
Page 151 and 152:
171. Geborek P, Crnkic M, Petersson
Page 153 and 154:
216. Schotte H, Willeke P, Mickholz
Page 155 and 156:
The Health Assessment Questionnaire
Page 157 and 158:
Cochrane Library (CENTRAL) 2005 Iss
Page 159 and 160:
Appendix 3 © Queen’s Printer and
Page 161:
TABLE 69 Studies excluded from clin
Page 164 and 165:
148 Appendix 4 TABLE 71 Meta-analys
Page 166 and 167:
150 Appendix 4 TABLE 73 Meta-analys
Page 168 and 169:
152 Appendix 4 Infliximab versus pl
Page 170 and 171:
154 Appendix 4 Infliximab plus MTX
Page 173:
Ovid MEDLINE(R) 1966 to February we
Page 177 and 178:
Appendix 8 © Queen’s Printer and
Page 179 and 180:
TABLE 79 Wong et al., 2002 161 © Q
Page 181 and 182:
TABLE 80 Kobelt et al., 2003 162 (c
Page 183 and 184:
TABLE 82 Brennan et al., 2004 160
Page 185 and 186:
Page 187 and 188:
TABLE 85 Bansback et al., 2005 166
Page 189:
Page 192 and 193: 176 Appendix 9 TABLE 89 Strategy se
Page 195 and 196: Extensive sensitivity analysis was
Page 197 and 198: TABLE 96 Variation 1: TNF inhibitor
Page 199 and 200: TABLE 99 Variation 2: TNF inhibitor
Page 201 and 202: TABLE 102 Variation 3: TNF inhibito
Page 221 and 222: TABLE 132 Variation 10: TNF inhibit
Page 241: TABLE 162 Variation 18: TNF inhibit
Page 247 and 248: Volume 1, 1997 No. 1 Home parentera
Page 249 and 250: No. 3 Screening for sickle cell dis
Page 251 and 252: No. 25 A rapid and systematic revie
Page 253 and 254: No. 11 First and second trimester a
Page 255 and 256: No. 23 Clinical effectiveness and c
Page 257 and 258: No. 28 Outcomes of electrically sti
Page 259: No. 28 Adefovir dipivoxil and pegyl
Page 262 and 263: 246 Health Technology Assessment Pr
Page 264: 248 Health Technology Assessment Pr
show all

A systematic review of the effectiveness of adalimumab

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?